Medical Xpress November 23, 2024
In a new analysis of national data, researchers at the Richard A. and Susan F. Smith Center for Outcomes Research at Beth Israel Deaconess Medical Center (BIDMC) estimated that 137 million U.S. adults, more than half of all adults, are eligible for semagludtide for weight loss, diabetes management, or prevention of recurrent cardiovascular events.
The findings, which were presented at the American Heart Association Scientific Sessions and simultaneously published in JAMA Cardiology, underscore the need to increase equitable access to this new class of pharmaceuticals.
“These staggering numbers mean that we are likely to see large increases in spending on semaglutide and related medications in years to come,” said corresponding author Dhruv S. Kazi, MD, MS, associate director of the...
Today's Sponsors
Today's Sponsor